$DNLI
Denali Therapeutics Inc. Stock $dnli

$dnli Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000171489921000033 Filed on February 26, 2021

Income Statement

Concept	2019 Q4	2019	2018
Revenue	$4.672M	$26.68M	$129.2M
YoY Change	-96.28%	-79.34%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.90M	$46.50M	$32.30M
YoY Change	-0.91%	43.96%	105.73%
% of Gross Profit
Research & Development	$51.60M	$193.4M	$143.2M
YoY Change	29.32%	35.06%	92.3%
% of Gross Profit
Depreciation & Amortization	$2.100M	$8.000M	$7.400M
YoY Change	-12.5%	8.11%	138.71%
% of Gross Profit
Operating Expenses	$62.40M	$239.9M	$175.5M
YoY Change	22.35%	36.65%	94.73%
Operating Profit	-$57.76M	-$213.2M	-$46.37M
YoY Change	-177.3%	359.73%	-48.56%
Interest Expense	$3.800M	$15.20M	$10.10M
YoY Change	35.71%	50.5%	405.0%
% of Operating Profit
Other Income/Expense, Net		$15.22M	$10.13M
YoY Change		50.21%	418.26%
Pretax Income	-$54.00M	-$198.0M	-$36.20M
YoY Change	-169.68%	446.96%	-58.96%
Income Tax	$100.0K	-$351.0K	$0.00
% Of Pretax Income
Net Earnings	-$54.03M	-$197.6M	-$36.24M
YoY Change	-169.68%	445.29%	-58.9%
Net Earnings / Revenue	-1156.36%	-740.74%	-28.06%
Basic Earnings Per Share		-$2.07	-$0.39
Diluted Earnings Per Share	-$561.9K	-$2.07	-$0.39
COMMON SHARES
Basic Shares Outstanding	96.03M shares	95.61M shares	92.62M shares
Diluted Shares Outstanding		95.61M shares	92.62M shares

Balance Sheet

Concept	2019 Q4	2019	2018
SHORT-TERM ASSETS
Cash & Short-Term Investments	$415.4M	$415.4M	$464.3M
YoY Change	-10.53%	-10.53%	14.3%
Cash & Equivalents	$79.45M	$79.40M	$77.10M
Short-Term Investments	$335.9M	$335.9M	$387.2M
Other Short-Term Assets	$14.70M	$14.70M	$15.40M
YoY Change	-10.91%	-4.55%	431.03%
Inventory
Prepaid Expenses
Receivables			$1.200M
Other Receivables			$0.00
Total Short-Term Assets	$430.0M	$430.0M	$480.8M
YoY Change	-10.57%	-10.57%	17.38%
LONG-TERM ASSETS
Property, Plant & Equipment	$46.73M	$80.70M	$25.20M
YoY Change	85.72%	220.24%	69.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$39.90M	$39.90M	$147.9M
YoY Change	-73.02%	-73.02%	141.27%
Other Assets	$2.659M	$2.700M	$8.100M
YoY Change	-67.19%	-66.67%	800.0%
Total Long-Term Assets	$123.2M	$123.2M	$181.2M
YoY Change	-31.99%	-32.01%	135.02%
TOTAL ASSETS
Total Short-Term Assets	$430.0M	$430.0M	$480.8M
Total Long-Term Assets	$123.2M	$123.2M	$181.2M
Total Assets	$553.2M	$553.2M	$662.0M
YoY Change	-16.43%	-16.44%	36.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.590M	$2.600M	$1.900M
YoY Change	36.96%	36.84%	-29.63%
Accrued Expenses	$6.569M	$24.00M	$18.50M
YoY Change	-22.9%	29.73%	76.19%
Deferred Revenue	$18.74M
YoY Change	63.99%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$45.34M	$45.30M	$32.80M
YoY Change	38.3%	38.11%	130.99%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$379.0K	$113.0M	$82.40M
YoY Change	-19.53%	37.14%	1111.76%
Total Long-Term Liabilities	$379.0K	$113.0M	$82.40M
YoY Change	-19.53%	37.14%	1111.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$45.34M	$45.30M	$32.80M
Total Long-Term Liabilities	$379.0K	$113.0M	$82.40M
Total Liabilities	$158.3M	$158.3M	$115.1M
YoY Change	37.52%	37.53%	450.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$425.6M
YoY Change	86.7%
Common Stock	$1.288M
YoY Change	1.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$394.9M	$394.9M	$546.8M
YoY Change
Total Liabilities & Shareholders Equity	$553.2M	$553.2M	$662.0M
YoY Change	-16.43%	-16.44%	36.02%

Cashflow Statement

Concept	2019 Q4	2019	2018
OPERATING ACTIVITIES
Net Income	-$54.03M	-$197.6M	-$36.24M
YoY Change	-169.68%	445.29%	-58.9%
Depreciation, Depletion And Amortization	$2.100M	$8.000M	$7.400M
YoY Change	-12.5%	8.11%	138.71%
Cash From Operating Activities	-$47.70M	-$151.6M	$50.12M
YoY Change	-151.18%	-402.45%	-165.4%
INVESTING ACTIVITIES
Capital Expenditures	-$2.800M	$17.92M	$3.393M
YoY Change	100.0%	428.12%	18.02%
Acquisitions
YoY Change
Other Investing Activities	$45.10M	$165.6M	-$284.0M
YoY Change	-175.29%	-158.31%	641.51%
Cash From Investing Activities	$42.40M	$147.7M	-$287.4M
YoY Change	-169.06%	-151.39%	598.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.000M	$6.190M	$97.02M
YoY Change	17.65%	-93.62%	-67.26%
NET CHANGE
Cash From Operating Activities	-47.70M	-$151.6M	$50.12M
Cash From Investing Activities	42.40M	$147.7M	-$287.4M
Cash From Financing Activities	2.000M	$6.190M	$97.02M
Net Change In Cash	-3.300M	$2.326M	-$140.3M
YoY Change	-109.85%	-101.66%	-178.58%
FREE CASH FLOW
Cash From Operating Activities	-$47.70M	-$151.6M	$50.12M
Capital Expenditures	-$2.800M	$17.92M	$3.393M
Free Cash Flow	-$44.90M	-$169.5M	$46.72M
YoY Change	-147.46%	-462.77%	-158.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001714899
CY2019Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-38311
CY2020	dei	Entity Registrant Name EntityRegistrantName	Denali Therapeutics Inc.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3872213
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	161 Oyster Point Blvd
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2020	dei	City Area Code CityAreaCode	650
CY2020	dei	Local Phone Number LocalPhoneNumber	866-8548
CY2020	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2020	dei	Trading Symbol TradingSymbol	DNLI
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	850600000	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	120984085	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	507144000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	79449000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	962553000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	335907000	USD
CY2020Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	5674000	USD
CY2019Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	0	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20284000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14675000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1495655000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	430031000	USD
CY2020Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	32699000	USD
CY2019Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	39886000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	40846000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	46732000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32618000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33923000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2462000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2659000	USD
CY2020Q4	us-gaap	Assets Assets	1604280000	USD
CY2019Q4	us-gaap	Assets Assets	553231000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1071000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2590000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	47145000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	24015000	USD
CY2020Q4	dnli	Contract With Customer Liability From Related Parties Current ContractWithCustomerLiabilityFromRelatedPartiesCurrent	3569000	USD
CY2019Q4	dnli	Contract With Customer Liability From Related Parties Current ContractWithCustomerLiabilityFromRelatedPartiesCurrent	0	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	19914000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	18739000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	71699000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	45344000	USD
CY2020Q4	dnli	Contract With Customer Liability From Related Parties Noncurrent ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent	293849000	USD
CY2019Q4	dnli	Contract With Customer Liability From Related Parties Noncurrent ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent	0	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	23325000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	43753000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	64175000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	68865000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	701000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	379000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	453749000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	158341000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	120531333	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	120531333	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96189935	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96189935	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1531000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1288000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1503660000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	818803000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-245000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	350000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-354415000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-425551000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1150531000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	394890000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1604280000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	553231000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	335561000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26320000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	129100000	USD
CY2020	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	98000	USD
CY2019	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	358000	USD
CY2018	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	60000	USD
CY2020	us-gaap	Revenues Revenues	335659000	USD
CY2019	us-gaap	Revenues Revenues	26678000	USD
CY2018	us-gaap	Revenues Revenues	129160000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	212615000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	193382000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	143183000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	60326000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	46480000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	32349000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	272941000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	239862000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	175532000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	62718000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-213184000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-46372000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9241000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15219000	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10132000	USD
CY2020	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	71959000	USD
CY2019	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-197965000	USD
CY2018	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-36240000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-823000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	351000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	71136000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-197614000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-36240000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-595000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	999000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-281000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	70541000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-196615000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36521000	USD
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.65
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.07
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.63
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.07
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	108974137	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95608208	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	92621991	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	112703108	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	95608208	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	92621991	shares
CY2020	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	307437000	USD
CY2020	dnli	Research And Development Expense Offset From Related Party Cost Reimbursement ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement	9260000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	465796000	USD
CY2018	dnli	Stock Issued During Period Value Collaboration Agreement StockIssuedDuringPeriodValueCollaborationAgreement	94406000	USD
CY2018	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	3999000	USD
CY2018	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	374000	USD
CY2018	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18791000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-36240000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-281000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	546845000	USD
CY2019	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	6190000	USD
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	92000	USD
CY2019	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7991000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	38378000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-197614000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	999000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	394890000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	193948000	USD
CY2020	dnli	Stock Issued During Period Value Stock Purchase Agreement StockIssuedDuringPeriodValueStockPurchaseAgreement	420146000	USD
CY2020	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	20655000	USD
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	50351000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	71136000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-595000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1150531000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	71136000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-197614000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-36240000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8531000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1033000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7415000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	50351000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	38378000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	18791000	USD
CY2020	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-55000	USD
CY2019	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	5019000	USD
CY2018	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	2705000	USD
CY2020	dnli	Increase Decrease In Non Cash Operating Lease Expense IncreaseDecreaseInNonCashOperatingLeaseExpense	2360000	USD
CY2019	dnli	Increase Decrease In Non Cash Operating Lease Expense IncreaseDecreaseInNonCashOperatingLeaseExpense	-2117000	USD
CY2018	dnli	Increase Decrease In Non Cash Operating Lease Expense IncreaseDecreaseInNonCashOperatingLeaseExpense	0	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-38000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	351000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	36000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	10569000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-6675000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	18290000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1623000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-526000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	22106000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1500000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	9113000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-19253000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-6286000	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	68777000	USD
CY2020	dnli	Increase Decrease In Contract With Customer Liability Related Parties IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties	297418000	USD
CY2019	dnli	Increase Decrease In Contract With Customer Liability Related Parties IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties	0	USD
CY2018	dnli	Increase Decrease In Contract With Customer Liability Related Parties IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties	0	USD
CY2020	dnli	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0	USD
CY2019	dnli	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0	USD
CY2018	dnli	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	3438000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	322000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	379000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	416152000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-151576000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	50116000	USD
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1285468000	USD
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	369696000	USD
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	557930000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3095000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17919000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3393000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	665357000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	535327000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	273901000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-623206000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	147712000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-287422000	USD
CY2020	dnli	Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement	420146000	USD
CY2019	dnli	Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement	0	USD
CY2018	dnli	Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement	94406000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	193948000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	20655000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6190000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3999000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	634749000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6190000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	97019000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	427695000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2326000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-140287000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	80949000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78623000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	218910000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	508644000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	80949000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78623000	USD
CY2020	dnli	Noncash Tenant Improvements Paid By Landlord NoncashTenantImprovementsPaidByLandlord	0	USD
CY2019	dnli	Noncash Tenant Improvements Paid By Landlord NoncashTenantImprovementsPaidByLandlord	11343000	USD
CY2018	dnli	Noncash Tenant Improvements Paid By Landlord NoncashTenantImprovementsPaidByLandlord	14561000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	67000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	335000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the Consolidated Balance Sheets and Consolidated Statements of Operations and Comprehensive Income (Loss).</span></div>
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and forward foreign currency exchange contracts. Substantially all of the Company’s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:1pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, 2020 and 2019, the Company had no off-balance sheet concentrations of credit risk.</span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to counterparty credit risk on all of its derivative financial instruments. The Company has established and maintains strict counterparty credit guidelines and enters into hedges only with financial institutions that are investment grade or better to minimize the Company’s exposure to potential defaults. The Company does not require collateral to be pledged under these agreements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, the ability to make milestone, royalty or other payments due under any license or collaboration agreements, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.</span></div>The COVID-19 pandemic has caused increased risk and uncertainty for the Company. Credit risk associated with investments in securities may increase if any institution with which the Company has an investment is significantly impacted by the COVID-19 pandemic.
CY2020Q4	dnli	Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk Amount ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRiskAmount	0	USD
CY2019Q4	dnli	Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk Amount ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRiskAmount	0	USD
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000.0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000.0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1500000	USD
CY2020Q4	us-gaap	Derivative Assets DerivativeAssets	185000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1480718000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1480718000	USD
CY2020Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	11000	USD
CY2020Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	11000	USD
CY2020Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	11000	USD
CY2020Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	11000	USD
CY2019Q4	us-gaap	Derivative Assets DerivativeAssets	85000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	446030000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	446030000	USD
CY2019Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	8000	USD
CY2019Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	8000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	995147000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	130000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	25000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	995252000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	375094000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	729000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	30000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	375793000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2019	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	400000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P2Y
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	100000	USD
CY2019	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	200000	USD
CY2018	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-200000	USD
CY2018Q4	dnli	Number Of Indications NumberOfIndications	3	indication
CY2018Q4	dnli	Number Of Indications NumberOfIndications	3	indication
CY2020	us-gaap	Revenues Revenues	335659000	USD
CY2019	us-gaap	Revenues Revenues	26678000	USD
CY2018	us-gaap	Revenues Revenues	129160000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	61648000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	59005000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20802000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12273000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	40846000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	46732000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8500000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8000000.0	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7400000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.090
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	20503000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8739000	USD
CY2020Q4	dnli	Accrued Clinical And Contract Research Organization Costs AccruedClinicalAndContractResearchOrganizationCosts	6497000	USD
CY2019Q4	dnli	Accrued Clinical And Contract Research Organization Costs AccruedClinicalAndContractResearchOrganizationCosts	5042000	USD
CY2020Q4	dnli	Other Accrued Manufacturing Costs OtherAccruedManufacturingCosts	7140000	USD
CY2019Q4	dnli	Other Accrued Manufacturing Costs OtherAccruedManufacturingCosts	2027000	USD
CY2020Q4	dnli	Other Accrued Research And Development Costs OtherAccruedResearchAndDevelopmentCosts	5278000	USD
CY2019Q4	dnli	Other Accrued Research And Development Costs OtherAccruedResearchAndDevelopmentCosts	3224000	USD
CY2020Q4	dnli	Accrued General Administrative And Shared Costs AccruedGeneralAdministrativeAndSharedCosts	3037000	USD
CY2019Q4	dnli	Accrued General Administrative And Shared Costs AccruedGeneralAdministrativeAndSharedCosts	1318000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4690000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3665000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	47145000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	24015000	USD
CY2020	us-gaap	Lease Cost LeaseCost	11100000	USD
CY2019	us-gaap	Lease Cost LeaseCost	10200000	USD
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	6000000.0	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y3M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.090
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	9700000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	10391000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10731000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	11083000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	11447000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	11824000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	42250000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	97726000	USD
CY2020	us-gaap	Sublease Income SubleaseIncome	3600000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	28861000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	68865000	USD
CY2019	us-gaap	Sublease Income SubleaseIncome	2600000	USD
CY2018	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	0	USD
CY2020Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	2925000	USD
CY2020Q4	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	3009000	USD
CY2020Q4	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	3096000	USD
CY2020Q4	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	876000	USD
CY2020Q4	dnli	Lessor Operating Lease Payment To Be Received After Year Four LessorOperatingLeasePaymentToBeReceivedAfterYearFour	0	USD
CY2020Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	9906000	USD
CY2020Q4	us-gaap	Contractual Obligation ContractualObligation	4800000	USD
CY2019Q4	us-gaap	Contractual Obligation ContractualObligation	1100000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11640734	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.96
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M14D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	51879000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3518298	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	26.24
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1487426	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	11.55
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	711680	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	20.57
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12959926	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.31
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.86
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M13D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	874026000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	11215194	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	18.75
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y9M14D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	717292000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5301186	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	14.28
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y11M12D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	368335000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	43800000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	13100000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	9800000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	11.51
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	10.09
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.85
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.67
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.79
CY2020	us-gaap	Dividends Dividends	0	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	50351000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	38378000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18791000	USD
CY2020	dnli	Share Based Payment Arrangement Vest Or Exercise Of Option Tax Benefit ShareBasedPaymentArrangementVestOrExerciseOfOptionTaxBenefit	1000000.0	USD
CY2018	dnli	Share Based Payment Arrangement Vest Or Exercise Of Option Tax Benefit ShareBasedPaymentArrangementVestOrExerciseOfOptionTaxBenefit	0	USD
CY2019	dnli	Share Based Payment Arrangement Vest Or Exercise Of Option Tax Benefit ShareBasedPaymentArrangementVestOrExerciseOfOptionTaxBenefit	0	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1900000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1600000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	900000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	823000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-338000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	823000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-13000	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-351000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.011
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.040
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.244
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.207
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.092
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.035
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.102
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.079
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.001
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.007
CY2020	dnli	Effective Income Tax Rate Reconciliation Nondeductible Expense Acquisition Related Costs EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAcquisitionRelatedCosts	0
CY2019	dnli	Effective Income Tax Rate Reconciliation Nondeductible Expense Acquisition Related Costs EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAcquisitionRelatedCosts	0
CY2018	dnli	Effective Income Tax Rate Reconciliation Nondeductible Expense Acquisition Related Costs EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAcquisitionRelatedCosts	-0.095
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.011
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	54110000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	56612000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	27411000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	19133000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	15344000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	13516000	USD
CY2020Q4	dnli	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	17179000	USD
CY2019Q4	dnli	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	15686000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	18709000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	9513000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	17767000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	11815000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	150520000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	126275000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	133054000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	112713000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	17466000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	13562000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	9329000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	6225000	USD
CY2020Q4	dnli	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	8137000	USD
CY2019Q4	dnli	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	7337000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	95608208	shares
CY2019Q4	dnli	Deferred Tax Assets Valuation Allowance Percent DeferredTaxAssetsValuationAllowancePercent	1
CY2020Q4	dnli	Deferred Tax Assets Valuation Allowance Percent DeferredTaxAssetsValuationAllowancePercent	1
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	20300000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5299000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2642000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1146000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	107000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3009000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2595000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1506000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	169000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	45000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	10000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8139000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5299000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2642000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	300000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2020Q4	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	71136000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-197614000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-36240000	USD
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	108974137	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95608208	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	92621991	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3728971	shares
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2018	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	112703108	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	92621991	shares
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.65
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.07
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.63
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.07
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4165837	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12804070	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10428261	shares

Files In Submission

Name	View Source	Status
0001714899-21-000033-index-headers.html	Edgar Link	pending
0001714899-21-000033-index.html	Edgar Link	pending
0001714899-21-000033.txt	Edgar Link	pending
0001714899-21-000033-xbrl.zip	Edgar Link	pending
dnli-20201231.htm	Edgar Link	pending
dnli-20201231.xsd	Edgar Link	pending
dnli-20201231_cal.xml	Edgar Link	unprocessable
dnli-20201231_def.xml	Edgar Link	unprocessable
dnli-20201231_g1.jpg	Edgar Link	pending
dnli-20201231_g10.jpg	Edgar Link	pending
dnli-20201231_g11.jpg	Edgar Link	pending
dnli-20201231_g12.jpg	Edgar Link	pending
dnli-20201231_g13.jpg	Edgar Link	pending
dnli-20201231_g14.jpg	Edgar Link	pending
dnli-20201231_g15.jpg	Edgar Link	pending
dnli-20201231_g2.jpg	Edgar Link	pending
dnli-20201231_g3.jpg	Edgar Link	pending
dnli-20201231_g4.jpg	Edgar Link	pending
dnli-20201231_g5.jpg	Edgar Link	pending
dnli-20201231_g6.jpg	Edgar Link	pending
dnli-20201231_g7.jpg	Edgar Link	pending
dnli-20201231_g8.jpg	Edgar Link	pending
dnli-20201231_g9.jpg	Edgar Link	pending
dnli-20201231_htm.xml	Edgar Link	completed
dnli-20201231_lab.xml	Edgar Link	unprocessable
dnli-20201231_pre.xml	Edgar Link	unprocessable
ex10124amendmentno5todmsa.htm	Edgar Link	pending
ex10125amendmentno3todmsa.htm	Edgar Link	pending
ex10126amendmentno6todmsa.htm	Edgar Link	pending
ex1015amendeddirectorcompe.htm	Edgar Link	pending
exhibit211q42020subsidiari.htm	Edgar Link	pending
exhibit231q42020.htm	Edgar Link	pending
exhibit311q42020.htm	Edgar Link	pending
exhibit312q42020.htm	Edgar Link	pending
exhibit321q42020.htm	Edgar Link	pending
exhibit322q42020.htm	Edgar Link	pending
exhibit43q42020description.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DNLI
Denali Therapeutics Inc. Stock $dnli

2019 Q4 Form 10-K Financial Statement

#000171489921000033 Filed on February 26, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DNLI Denali Therapeutics Inc. Stock $dnli

2019 Q4 Form 10-K Financial Statement

#000171489921000033 Filed on February 26, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DNLI
Denali Therapeutics Inc. Stock $dnli